

References and Suggested Reading

Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL): Managing New and Current Patients Reducing Risk

Adams WP Jr, Conner WC, Barton FE, Rohrich RJ. Optimizing breast pocket irrigation: an in vitro study and clinical implications. *Plast Reconstr Surg*. 2000;105(1):334-338.

Adams WP Jr, Culbertson EJ, Deva AK, et al. macrot textured breast implants with defined steps to minimize bacterial contamination around the device: experience in 42,000 implants. *Plast Reconstr Surg*. 2017;140(3):427-431.

Afshari A, Nguyen L, Glassman GE, et al. Incidence and preoperative risk factors for major complications after capsulectomy: analysis of 3,048 patients. *Aesthet Surg J*. January 12, 2022. Online ahead of print. doi: 10.1093/asj/sjac004

Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J*. 2017;37(3):285-289.

Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. *J Clin Oncol*. 2016;34(2):160-168.

Collins MS, Miranda RN, Medeiros LJ, et al. Characteristics and treatment of advanced breast implant-associated anaplastic large cell lymphoma. *Plast Reconstr Surg*. 2019;143(3S):41S-50S.

Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. *J Plast Reconstr Aesthet Surg*. 2020;73(5):841-846.

Culbertson EJ, Scott CF, Deva AK, Greenberg DE, Adams WP. Optimizing breast pocket irrigation: the breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) era. *Aesthet Surg J*. 2020;40(6):619-625.

de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. *JAMA Oncol*. 2018;4(3):335-341.

de Jong D, Vasmel WLE, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. *JAMA*. 2008;300(17):2030-2035.

Deva AK, Turner SD, Kadin ME, et al. Etiology of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): current directions in research. *Cancers*. 2020;12(12):3861.

Deva AK, Adams WP Jr, Vickery K. The role of bacterial biofilms in device-associated infection. *Plast Reconstr Surg*. 2013;132(5):1319-1328.

Doren EL, Miranda RN, Selber JC, et al. U.S. Epidemiology of breast implant-associated anaplastic large cell lymphoma. *Plast Reconstr Surg*. 2017;139(5):1042-1050.

FDA Breast Implants. 10/27/21. Accessed 3/18/22. https://www.fda.gov/medical-devices/implants-and-prosthetics/breast-implants?utm_campaign=FDA+Strengthens+Safety+Requirements+and+Updates+Study+Results+fo&utm_medium=email&utm_source=govdelivery

FDA. Allergan voluntarily recalls BIOCELL textured breast implants and tissue expanders. 7/25/19. Accessed 3/18/22. <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/allergan-voluntarily-recalls-biocellr-textured-breast-implants-and-tissue-expanders>

FDA. Questions and answers about breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). 10/23/19. Accessed 3/18/22. <https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl>.

FDA. The FDA requests Allergan voluntarily recall Natrelle BIOCELL textured breast implants and tissue expanders from the market to protect patients: FDA Safety Communication. Updated 6/1/20. Accessed 3/18/22. <https://www.fda.gov/medical-devices/safety-communications/fda-requests-allergan-voluntarily-recall-natrelle-biocell-textured-breast-implants-and-tissue#list>

Jacombs A, Tahir S, Hu H, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. *Plast Reconstr Surg*. 2014;133(4):471e-480e.

Kadin ME, Adams WP Jr, Inghrami G, Di Napoli A. Does breast implant-associated ALCL begin as a lymphoproliferative disorder? *Plast Reconstr Surg*. 2020;145(1):30e-38e.

Kadin ME, Morgan J, Xu H, Glicksman CA. CD30+ T cells in late seroma may not be diagnostic of breast implant-associated anaplastic large cell lymphoma. *Aesthet Surg J*. 2017;37(7):771-775.

Keech KA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. *Plast Reconstr Surg*. 1997;100(2):554-555.

Lee JH. Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). *Yeungnam Univ J Med*. 2021;38(3):175-182.

Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant-associated anaplastic large cell lymphoma in australia and new zealand: high-surface-area textured implants are associated with increased risk. *Plast Reconstr Surg*. 2017;140(4):645-654.

Lyapichev KA, Oina-Oviedo S, Medeiros LJ, et al. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. *Mod Pathol*. 2020;33(3):367-379.

Magnusson MR, Deva AK. Letter to Editor: Fleming D, Stone J, Tansley P. spontaneous regression and resolution of breast implant-associated anaplastic large cell lymphoma: implications for research, diagnosis and clinical management, APS 2018. *Aesthet Plast Surg*. 2018;42(4):1164-1166.

McGuire P, Reisman NR, Murphy DK. Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving Natrelle 410 form-stable silicone breast implants. *Plast Reconstr Surg*. 2017;139(1):1-9.

Mehta-Shah N, Clemens MW, Horwitz SM. How I treat breast implant-associated anaplastic large cell lymphoma. *Blood*. 2018;132(18):1889-1898.

National Aeronautics and Space Administration. June 24, 2016. Accessed April 6, 2022. www.nasa.gov/feature/jpl/nasa-technology-applied-in-breast-cancer-study

NCCN Guidelines Version 1.2020 Breast implant-associated ALCL. Accessed 3/18/22. <https://biaalcl.com/wp-content/uploads/NCCN-Guidelines-January-2020.pdf>

NCCN Guidelines Version 1.2020 Breast implant-associated ALCL. Accessed 3/18/22. <https://biaalcl.com/wp-content/uploads/NCCN-Guidelines-January-2020.pdf>

Park JO, Webb CE, Temple-Oberle CF. Navigating women's BIA-ALCL information needs: group seminars

may offer an opportunity to empower the patient-surgeon team. *Plast Reconstr Surg Glob Open*. 2020;8(9):e3142.

Park JO, Webb CE, Temple-Oberle CF. Supporting women's BIA-ALCL decision-making: role of the individual consult in empowering the patient-physician team. *Plast Reconstr Surg Glob Open*. 2021;9(10):e3843.

Sieber DA, Adams WP Jr. What's your micromort? a patient-oriented analysis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). *Aesthet Surg J*. 2017;37(8):887-891.

Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood*. 2016;127(20):2375-2390.

Turton P, El-Sharkawi D, Lyburn I, et al. UK Guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). *J Plast Reconstr Aesthet Surg*. 2021;74(1):13-29.

US Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA findings and analyses. January 2011. Accessed 4/28/11. <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm#review>

Ye X, Shokrollahi K, Rozen WM, et al. Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence. *Mutat Res Rev Mutat Res*. 2014;762:123-132.